{"id":36936,"date":"2026-06-06T03:01:05","date_gmt":"2026-06-05T21:31:05","guid":{"rendered":"https:\/\/atsixty.com\/?p=36936"},"modified":"2026-06-06T09:41:16","modified_gmt":"2026-06-06T04:11:16","slug":"morning-rounds-rheumatology-series","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/","title":{"rendered":"Morning Rounds: Rheumatology Series"},"content":{"rendered":"\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&amp;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&amp;display=swap\" rel=\"stylesheet\">\n<style>\n\/* ============================================================\n   Morning Rounds \u00b7 Rheumatology Series Index\n   Namespace: #rheum-index\n   Palette: terracotta (Rheumatology series standard)\n   ============================================================ *\/\n#rheum-index *,#rheum-index *::before,#rheum-index *::after{box-sizing:border-box;margin:0;padding:0}\n#rheum-index{\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;\n  color:#2C1810;\n  background:#FAF6F2;\n  line-height:1.8;\n  padding:0 0 64px;\n}\n#rheum-index .di-header{\n  background:#8B3D20;\n  color:#FFFDF9;\n  padding:36px 24px 30px;\n  text-align:center;\n}\n#rheum-index .di-eyebrow{\n  font-size:0.68rem;\n  letter-spacing:0.18em;\n  text-transform:uppercase;\n  font-weight:600;\n  opacity:0.65;\n  margin-bottom:10px;\n}\n#rheum-index .di-title{\n  font-family:'Playfair Display',serif;\n  font-size:1.9rem;\n  font-weight:700;\n  line-height:1.2;\n  margin-bottom:6px;\n}\n#rheum-index .di-title em{\n  font-style:italic;\n  font-weight:400;\n  opacity:0.88;\n}\n#rheum-index .di-subtitle{\n  font-size:0.85rem;\n  opacity:0.72;\n  font-style:italic;\n  margin-top:8px;\n}\n#rheum-index .di-body{\n  max-width:740px;\n  margin:0 auto;\n  padding:0 20px;\n}\n#rheum-index .di-intro{\n  margin:36px 0 28px;\n  font-size:0.97rem;\n  color:#3A2418;\n  line-height:1.82;\n}\n#rheum-index .di-intro p{\n  margin-bottom:1.1em;\n}\n#rheum-index .di-intro p:last-child{\n  margin-bottom:0;\n}\n#rheum-index .di-section-head{\n  font-family:'Playfair Display',serif;\n  font-size:1.15rem;\n  font-weight:700;\n  color:#8B3D20;\n  margin:36px 0 18px;\n  padding-bottom:6px;\n  border-bottom:2px solid #E8C8B8;\n}\n#rheum-index .di-card{\n  background:#FFFDF9;\n  border:1px solid #E8DDD8;\n  border-left:4px solid #8B3D20;\n  border-radius:10px;\n  padding:18px 20px 16px;\n  margin-bottom:16px;\n  box-shadow:0 1px 5px rgba(139,61,32,0.06);\n}\n#rheum-index .di-card-num{\n  font-size:0.62rem;\n  font-weight:700;\n  letter-spacing:0.14em;\n  text-transform:uppercase;\n  color:#8B3D20;\n  opacity:0.7;\n  margin-bottom:4px;\n}\n#rheum-index .di-card-title{\n  font-family:'Playfair Display',serif;\n  font-size:1.05rem;\n  font-weight:700;\n  color:#2C1810;\n  margin-bottom:6px;\n}\n#rheum-index .di-card-body{\n  font-size:0.88rem;\n  color:#5A3D30;\n  line-height:1.7;\n  margin-bottom:12px;\n}\n#rheum-index .di-card-link{\n  display:inline-block;\n  background:#8B3D20;\n  color:#FFFDF9;\n  text-decoration:none;\n  font-family:'Playfair Display',serif;\n  font-size:0.82rem;\n  font-weight:700;\n  padding:7px 18px;\n  border-radius:6px;\n  transition:background 0.15s;\n}\n#rheum-index .di-card-link:hover{\n  background:#6B2D14;\n}\n#rheum-index .di-beyond{\n  background:#FFFDF9;\n  border:1px solid #E8DDD8;\n  border-radius:10px;\n  padding:20px 22px;\n  margin:28px 0 0;\n  font-size:0.88rem;\n  color:#5A3D30;\n  line-height:1.72;\n}\n#rheum-index .di-beyond-head{\n  font-family:'Playfair Display',serif;\n  font-size:0.95rem;\n  font-weight:700;\n  color:#2C1810;\n  margin-bottom:8px;\n}\n#rheum-index .di-feedback{\n  margin-top:36px;\n  padding:22px 22px 20px;\n  background:#FDF0EB;\n  border:1px solid #E8C8B8;\n  border-radius:10px;\n  font-size:0.88rem;\n  color:#5A3D30;\n  line-height:1.72;\n}\n#rheum-index .di-feedback-head{\n  font-family:'Playfair Display',serif;\n  font-size:0.95rem;\n  font-weight:700;\n  color:#8B3D20;\n  margin-bottom:8px;\n}\n#rheum-index .di-note{\n  margin-top:32px;\n  font-size:0.82rem;\n  color:#9A7060;\n  font-style:italic;\n  text-align:center;\n  line-height:1.6;\n}\n@media(max-width:480px){\n  #rheum-index .di-title{font-size:1.5rem}\n  #rheum-index .di-card{padding:14px 16px 13px}\n}\n<\/style>\n\n<div id=\"rheum-index\">\n\n  <div class=\"di-header\">\n    <div class=\"di-eyebrow\">Morning Rounds \u00b7 Rheumatology Series<\/div>\n    <div class=\"di-title\">\n      Rheumatology<br><em>A Guide to the Morning Rounds Series<\/em>\n    <\/div>\n    <div class=\"di-subtitle\">Seven high-yield rounds \u00b7 35 clinical cases \u00b7 NEET-PG and UPSC CMS \u00b7 +4 \/ \u22121 scoring<\/div>\n  <\/div>\n\n  <div class=\"di-body\">\n\n    <div class=\"di-intro\">\n      <p>Rheumatology is examined with a particular kind of cruelty in competitive postgraduate entrance tests. The diseases overlap, the antibodies are plentiful, the drug mechanisms are intricate, and the clinical presentations mimic each other across half a dozen conditions. A young woman with fatigue, joint pain, and a raised ESR could be RA, SLE, Sjogren's, MCTD, or early scleroderma \u2014 and the examiner knows you know that. What separates candidates is not pattern recognition alone, but the ability to apply the right diagnostic criterion, the right antibody, the right drug, and the right complication to the right disease under time pressure.<\/p>\n      <p>This series of seven Morning Rounds covers the full rheumatology curriculum as tested in NEET-PG and UPSC CMS. The first round on Rheumatology Clinical Reasoning is an existing post on this site and anchors the series \u2014 covering crystal arthropathy under polarised light, RA treatment escalation by EULAR criteria, SLE nephritis class and complement consumption, GCA and the visual emergency protocol, and axial SpA with ASAS inflammatory back pain criteria. Rounds Two through Seven build outward from there, with no repeated ground and no repeated question angles.<\/p>\n      <p>Each round carries five clinical cases with full debrief explanations and Extra Points \u2014 the paragraph after the dashed line that carries the exam-edge material: the criteria table, the drug interaction, the complication that defines the prognosis. The rounds are self-contained and can be taken in any order, but the sequence below is the recommended one: it moves from the most commonly tested conditions outward to the more specialised, and ends with a mixed paper that mirrors the random cross-cutting style of the actual exam.<\/p>\n    <\/div>\n\n    <div class=\"di-section-head\">The Seven Rounds<\/div>\n\n    <!-- Round 1 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 01 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Rheumatology Clinical Reasoning<\/div>\n      <div class=\"di-card-body\">\n        The anchor round for this series, covering five high-yield topics drawn from across the rheumatology spectrum. Crystal arthropathy under compensated polarised light microscopy: MSU crystals in a thiazide-treated patient, with the birefringence pattern, the crystal shape, and the trap of a normal serum uric acid during an acute attack. RA treatment escalation: the EULAR 2022 decision to add a TNF inhibitor to methotrexate when poor prognostic markers are present and a cDMARD has failed at adequate dose. SLE Class IV lupus nephritis: the ISN\/RPS classification, the mechanism of low C3 and C4 through classical pathway consumption, and induction therapy. GCA with visual threat: the protocol for immediate high-dose prednisolone before biopsy when amaurosis fugax has occurred, and why delaying treatment for histology is the most consequential clinical error in the disease. Axial SpA: the ASAS inflammatory back pain criteria and how this patient satisfies all five features including nocturnal improvement on getting up.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-clinical\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 2 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 02 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">SLE &amp; Antiphospholipid Syndrome<\/div>\n      <div class=\"di-card-body\">\n        Five cases in depth on systemic lupus erythematosus and its antiphospholipid overlap, with deliberate attention to the distinctions that examiners test rather than the ones textbooks repeat. ANA patterns and disease-specific antibodies: the homogeneous pattern with anti-dsDNA and anti-Sm, versus speckled with anti-RNP and anti-Sm, versus nucleolar with anti-Scl-70 \u2014 and why anti-SSA and anti-SSB belong to Sjogren's first and SLE second. The 2019 ACR\/EULAR classification criteria with weighted scoring across seven domains, and why renal biopsy is not required for classification. Drug-induced lupus: hydralazine, anti-histone antibody as the hallmark, absent anti-dsDNA, and full reversibility on stopping the drug. Primary APS: the 12-week interval rule for antibody confirmation, the triple-positivity risk, and the warfarin INR target versus why DOACs are avoided. Neonatal lupus: anti-SSA crossing the placenta, the congenital heart block risk, and the fetal echocardiography surveillance window from 16 to 26 weeks.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/sle-antiphospholipid-syndrome\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 3 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 03 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Seronegative Spondyloarthropathies<\/div>\n      <div class=\"di-card-body\">\n        Ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and IBD-associated SpA \u2014 grouped as they appear in examination papers, which is to say together and with enough overlap to confuse. AS and the radiological progression: the difference between syndesmophytes (thin, vertical, marginal, outer annulus fibrosus) and the osteophytes of DISH, how sacroiliitis is graded from 0 to IV, and why MRI detects active disease years before plain X-ray changes. Reactive arthritis: the post-enteric trigger, the sterile joint, keratoderma blennorrhagica as the pathognomonic skin finding, circinate balanitis, and why a negative Chlamydia swab does not exclude the diagnosis. Psoriatic arthritis: the five clinical patterns including the destructive arthritis mutilans with its pencil-in-cup deformity, the CASPAR criteria, and dactylitis as combined tenosynovitis. AS treatment: why BASDAI \u22654 after two NSAID failures justifies a biologic directly, without a cDMARD bridge \u2014 the fundamental distinction from RA. IBD-associated SpA: axial disease runs independently of bowel activity, and IL-17 inhibitors are contraindicated in Crohn's disease.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/seronegative-spondyloarthropathies\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 4 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 04 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Crystal Arthropathies<\/div>\n      <div class=\"di-card-body\">\n        The full spectrum of crystal-induced joint disease, deliberately avoiding the birefringence question already answered in Round One and instead targeting the clinical and pharmacological angles that remain high-yield and under-tested. Gout diagnosis without microscopy: the ACR 2015 classification criteria, the ultrasound double contour sign, dual-energy CT, and the critical fact that a normal serum uric acid during an acute attack does not exclude the diagnosis because SUA falls transiently under cytokine-driven uricosuria. ULT timing and targets: why allopurinol is started two to four weeks after the acute attack resolves, why mobilisation flares require prophylactic colchicine for the first three to six months, and the SUA target of under 6 mg\/dL. Gout in CKD: the evidence against the old dose-cap for allopurinol, the uricosuric effect of losartan, the role of SGLT2 inhibitors, and why NSAIDs are avoided and colchicine is dose-reduced when eGFR falls below 30. CPPD and pseudogout: the HATCH metabolic conditions, crowned dens syndrome, and the absence of any urate-lowering equivalent. Milwaukee shoulder: hydroxyapatite invisible on standard polarised light, the triad of large effusion plus rotator cuff tear plus glenohumeral destruction, and the alizarin red S stain.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/crystal-arthropathies\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 5 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 05 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Vasculitides<\/div>\n      <div class=\"di-card-body\">\n        The Chapel Hill Consensus classification from large to small vessel, with five cases chosen to represent the most examined entities and the most consequential clinical decisions. Takayasu arteritis: the young woman with BP asymmetry and a subclavian bruit, MR angiography as the investigation of choice, Numano classification types, and the distinction from GCA by age, ethnicity, and biopsy technique. GPA (Wegener's): the pulmonary-renal syndrome as a haematological emergency, pauci-immune crescentic GN with no immune deposits on immunofluorescence, c-ANCA\/PR3 positivity, and the choice between cyclophosphamide and rituximab for induction. PAN: the disease that has no glomerulonephritis, no pulmonary involvement, and negative ANCA \u2014 the three negatives that define it \u2014 with microaneurysms on angiography, mononeuritis multiplex, testicular artery involvement, and antiviral therapy for HBV-associated disease alongside corticosteroids. EGPA (Churg-Strauss): the three-phase progression from asthma through tissue eosinophilia to vasculitis, cardiac eosinophilic myocarditis as the leading cause of death, the Five Factor Score, and mepolizumab for relapsing disease. GCA without cranial symptoms: the PMR overlap, the temporal artery halo sign on ultrasound replacing biopsy in experienced centres, tocilizumab from the GiACTA trial, and large-vessel GCA detected on PET-CT.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-vasculitides\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 6 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 06 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Myopathies, Sjogren's &amp; Scleroderma<\/div>\n      <div class=\"di-card-body\">\n        Five conditions grouped by their shared tendency to produce overlapping clinical pictures and to demand antibody-level discrimination. Dermatomyositis and the antisynthetase syndrome: Gottron's papules and heliotrope rash as the pathognomonic skin findings of DM, anti-Jo-1 as the prototype antisynthetase antibody predicting the full cluster of ILD, inflammatory arthritis, mechanic's hands, and Raynaud's phenomenon, and ILD as the leading cause of mortality. The full myositis-specific antibody table in the Extra Points panel: anti-Mi-2, anti-MDA5 with its rapidly progressive ILD, anti-TIF1-\u03b3 with its malignancy association, anti-SRP, and anti-HMGCR. Steroid myopathy as the clinical trap that recurs in every exam diet: normal CK, normal ESR, no spontaneous activity on EMG, and the correct response of reducing the prednisolone dose rather than increasing it. Scleroderma renal crisis: the emergency of acute hypertension with microangiopathic haemolysis in early diffuse SSc, captopril as the treatment regardless of creatinine level, and prednisolone \u226515 mg\/day as the precipitating drug. MCTD: high-titre anti-U1-RNP as the defining antibody in the absence of disease-specific antibodies, puffy hands as the underappreciated clinical clue, and pulmonary arterial hypertension as the leading cause of death.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-myopathies-sjogrens-scleroderma\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Round 7 -->\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Round 07 \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Mixed High-Yield Round \u2014 Exam Simulation<\/div>\n      <div class=\"di-card-body\">\n        Five cases drawn from across the full rheumatology spectrum, designed to replicate the cross-cutting, unpredictable style of the actual NEET-PG and UPSC CMS paper. Felty's syndrome: the triad of seropositive RA with splenomegaly and neutropaenia, the mechanism of neutrophil destruction through splenic sequestration and anti-neutrophil antibodies, the requirement to exclude large granular lymphocyte leukaemia before attributing the picture to Felty's, and G-CSF for recurrent infection. Hydroxychloroquine dosing and toxicity: the revised maximum dose of 5 mg\/kg of actual body weight (not the older 6.5 mg\/kg of ideal body weight), annual retinal screening with SD-OCT from year five, bull's-eye maculopathy as the indication to stop, and why retinal damage is largely irreversible. Raynaud's phenomenon primary versus secondary: nail-fold capillaroscopy as the single best discriminating investigation, the scleroderma capillaroscopic pattern predicting CTD development, and the LeRoy-Medsger very early SSc criteria. Methotrexate pneumonitis: the idiosyncratic hypersensitivity mechanism, BAL CD4+ lymphocytosis, the fact that folic acid does not prevent pneumonitis, and the firm instruction not to restart MTX after confirmed pneumonitis. An integrated autoantibody case across four CTDs: which antibody in which patient predicts PAH as the leading cause of death \u2014 testing the anti-centromere versus anti-Scl-70 versus anti-U1-RNP distinction that resolves the majority of rheumatology prognosis questions.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-mixed-high-yield\/\" target=\"_blank\" rel=\"noopener\">Open Round \u2192<\/a>\n    <\/div>\n\n    <!-- Summative Revision -->\n    <div class=\"di-section-head\">Closing the Series<\/div>\n\n    <div class=\"di-card\">\n      <div class=\"di-card-num\">Summative Revision \u00b7 Rheumatology Series<\/div>\n      <div class=\"di-card-title\">Rheumatology Summative Revision Notes<\/div>\n      <div class=\"di-card-body\">\n        A structured revision document covering all seven rounds. Includes the ACR\/EULAR criteria for RA, SLE, and GCA; the ISN\/RPS lupus nephritis classification; the ASAS biologic threshold for axial SpA; the three-crystal comparison table for MSU, CPPD, and hydroxyapatite; the Chapel Hill vasculitis classification by vessel size; the myositis-specific antibody table; the scleroderma subtype and antibody grid; the leading-cause-of-death table by CTD; and the complete autoantibody master reference. Read this after working through the rounds, not before.\n      <\/div>\n      <a class=\"di-card-link\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-summative-revision\/\" target=\"_blank\" rel=\"noopener\">Open Notes \u2192<\/a>\n    <\/div>\n\n    <!-- Topics not covered -->\n    <div class=\"di-beyond\">\n      <div class=\"di-beyond-head\">Topics not covered in this series<\/div>\n      This series is thorough for NEET-PG and UPSC CMS purposes but is not a comprehensive rheumatology textbook. Areas outside these seven rounds include juvenile idiopathic arthritis (JIA) and its subtypes, adult-onset Still's disease, Behcet's disease, relapsing polychondritis, familial Mediterranean fever and other autoinflammatory syndromes, fibromyalgia and chronic pain syndromes, and orthopaedic rheumatology (osteoarthritis, osteoporosis, metabolic bone disease). These topics carry lighter but non-zero examination weight and are better addressed through a dedicated supplementary round or a targeted question bank after this series has been completed.\n    <\/div>\n\n    <!-- Feedback -->\n    <div class=\"di-feedback\">\n      <div class=\"di-feedback-head\">A note for doctor-examinees<\/div>\n      Rheumatology is genuinely difficult to teach well at the examination level because the diseases are defined by patterns \u2014 antibody patterns, clinical overlap patterns, therapeutic response patterns \u2014 rather than by a single pathognomonic finding. The cases in this series have been written to test those patterns rather than isolated facts, and the distractors have been written to be genuinely plausible rather than easily eliminated. If you found a case that was unfair, inaccurate, or misjudged in difficulty \u2014 or if you found one that taught you something you did not expect to find in a quiz format \u2014 the contact page is always open. That feedback shapes the next series.\n    <\/div>\n\n    <div class=\"di-note\">\n      Morning Rounds \u00b7 atsixty.com \u00b7 Rheumatology Series \u00b7 Seven rounds \u00b7 35 high-yield clinical cases \u00b7 +4 \/ \u22121 scoring \u00b7 NEET-PG and UPSC CMS\n    <\/div>\n\n  <\/div>\n<\/div>\n\n\n\n<p class=\"has-text-align-right wp-block-paragraph\"><a href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-clinical\/\" type=\"link\" id=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/rheumatology-clinical\/\">Rheumatology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Rheumatology Series RheumatologyA Guide to the Morning Rounds Series Seven high-yield rounds \u00b7 35 clinical cases \u00b7 NEET-PG and UPSC CMS \u00b7 +4 \/ \u22121 scoring Rheumatology is examined with a particular kind of cruelty in competitive postgraduate entrance tests. The diseases overlap, the antibodies are plentiful, the drug mechanisms are intricate,&hellip;&nbsp;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,24,64],"tags":[],"class_list":["post-36936","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-neet-pg","category-orthopaedics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Morning Rounds: Rheumatology Series - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Morning Rounds: Rheumatology Series - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Rheumatology Series RheumatologyA Guide to the Morning Rounds Series Seven high-yield rounds \u00b7 35 clinical cases \u00b7 NEET-PG and UPSC CMS \u00b7 +4 \/ \u22121 scoring Rheumatology is examined with a particular kind of cruelty in competitive postgraduate entrance tests. The diseases overlap, the antibodies are plentiful, the drug mechanisms are intricate,&hellip;&nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T21:31:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-06T04:11:16+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Morning Rounds: Rheumatology Series\",\"datePublished\":\"2026-06-05T21:31:05+00:00\",\"dateModified\":\"2026-06-06T04:11:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/\"},\"wordCount\":1883,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"Morning Rounds\",\"NEET PG\",\"Orthopaedics\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/\",\"name\":\"Morning Rounds: Rheumatology Series - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-05T21:31:05+00:00\",\"dateModified\":\"2026-06-06T04:11:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/morning-rounds-rheumatology-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Morning Rounds: Rheumatology Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Morning Rounds: Rheumatology Series - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/","og_locale":"en_US","og_type":"article","og_title":"Morning Rounds: Rheumatology Series - atsixty","og_description":"Morning Rounds \u00b7 Rheumatology Series RheumatologyA Guide to the Morning Rounds Series Seven high-yield rounds \u00b7 35 clinical cases \u00b7 NEET-PG and UPSC CMS \u00b7 +4 \/ \u22121 scoring Rheumatology is examined with a particular kind of cruelty in competitive postgraduate entrance tests. The diseases overlap, the antibodies are plentiful, the drug mechanisms are intricate,&hellip;&nbsp;","og_url":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/","og_site_name":"atsixty","article_published_time":"2026-06-05T21:31:05+00:00","article_modified_time":"2026-06-06T04:11:16+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Morning Rounds: Rheumatology Series","datePublished":"2026-06-05T21:31:05+00:00","dateModified":"2026-06-06T04:11:16+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/"},"wordCount":1883,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["Morning Rounds","NEET PG","Orthopaedics"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/","url":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/","name":"Morning Rounds: Rheumatology Series - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-05T21:31:05+00:00","dateModified":"2026-06-06T04:11:16+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/morning-rounds-rheumatology-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Morning Rounds: Rheumatology Series"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=36936"}],"version-history":[{"count":9,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36936\/revisions"}],"predecessor-version":[{"id":36963,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36936\/revisions\/36963"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=36936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=36936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=36936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}